B. Riley Trims X4 Pharmaceuticals (NASDAQ:XFOR) Target Price to $7.00

X4 Pharmaceuticals (NASDAQ:XFORGet Rating) had its price objective cut by B. Riley from $10.00 to $7.00 in a report released on Thursday, The Fly reports. They currently have a buy rating on the stock.

Several other analysts also recently commented on XFOR. HC Wainwright reduced their target price on shares of X4 Pharmaceuticals from $11.00 to $8.50 in a report on Friday, May 13th. Zacks Investment Research cut X4 Pharmaceuticals from a buy rating to a hold rating in a report on Thursday, February 17th. Stifel Nicolaus lowered their target price on X4 Pharmaceuticals from $19.00 to $10.00 in a research note on Thursday, March 17th. Canaccord Genuity Group decreased their price objective on X4 Pharmaceuticals from $20.00 to $10.00 and set a buy rating on the stock in a report on Tuesday, April 5th. Finally, Canaccord Genuity Group dropped their target price on X4 Pharmaceuticals from $20.00 to $10.00 in a report on Tuesday, April 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of Buy and an average price target of $10.61.

X4 Pharmaceuticals stock opened at $1.16 on Thursday. The company has a market cap of $35.76 million, a price-to-earnings ratio of -0.34 and a beta of 0.62. The firm has a 50-day moving average of $1.51 and a 200-day moving average of $2.27. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.73 and a quick ratio of 4.73. X4 Pharmaceuticals has a one year low of $1.00 and a one year high of $9.90.

X4 Pharmaceuticals (NASDAQ:XFORGet Rating) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.10). During the same period in the prior year, the company posted ($1.30) earnings per share. As a group, sell-side analysts expect that X4 Pharmaceuticals will post -2.43 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Asset Management L.P. bought a new position in shares of X4 Pharmaceuticals in the 4th quarter valued at $3,740,000. Altium Capital Management LP acquired a new position in X4 Pharmaceuticals in the 3rd quarter worth about $4,256,000. Bank of New York Mellon Corp acquired a new stake in shares of X4 Pharmaceuticals during the first quarter valued at about $246,000. Kennedy Capital Management Inc. acquired a new stake in shares of X4 Pharmaceuticals during the fourth quarter valued at about $301,000. Finally, Acadian Asset Management LLC acquired a new position in shares of X4 Pharmaceuticals in the fourth quarter valued at approximately $130,000. 76.63% of the stock is owned by institutional investors and hedge funds.

About X4 Pharmaceuticals (Get Rating)

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia.

Further Reading

The Fly logo

Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.